• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    12/22/22 12:32:46 PM ET
    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVO alert in real time by email

    Gainers

    • IsoPlexis (NASDAQ:ISO) stock moved upwards by 131.1% to $1.59 during Thursday's regular session. Trading volume for IsoPlexis's stock is 33.5 million as of 12:30 EST. This is 80056.9% of its average full-day volume over the last 100 days. The company's market cap stands at $63.1 million.
    • Scopus BioPharma (NASDAQ:SCPS) shares moved upwards by 76.61% to $0.11. As of 12:30 EST, this security is trading at a volume of 293.1K shares, making up 30.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 million.
    • ORIC Pharmaceuticals (NASDAQ:ORIC) stock moved upwards by 55.56% to $4.67. The current volume of 25.5 million shares is 23562.9% of ORIC Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $184.7 million.
    • Baudax Bio (NASDAQ:BXRX) stock rose 29.64% to $2.93. As of 12:30 EST, Baudax Bio's stock is trading at a volume of 608.4K, which is 102.9% of its average full-day volume over the last 100 days. The company's market cap stands at $1.6 million.
    • Alvotech (NASDAQ:ALVO) shares rose 20.6% to $10.01. The current volume of 707.9K shares is 1579.8% of Alvotech's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $2.4 billion.
    • Mereo BioPharma Group (NASDAQ:MREO) shares moved upwards by 20.06% to $0.68. As of 12:30 EST, Mereo BioPharma Group's stock is trading at a volume of 467.9K, which is 95.4% of its average full-day volume over the last 100 days. The company's market cap stands at $84.9 million.

    Losers

    • Lannett (NYSE:LCI) stock declined by 20.9% to $0.68 during Thursday's regular session. The current volume of 423.0K shares is 248.5% of Lannett's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $28.5 million.
    • Celyad Oncology (NASDAQ:CYAD) stock decreased by 20.4% to $0.57. The market value of their outstanding shares is at $12.9 million.
    • 180 Life Sciences (NASDAQ:ATNF) stock decreased by 20.38% to $1.68. As of 12:30 EST, this security is trading at a volume of 942.7K shares, making up 175.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.3 million.
    • Immuron (NASDAQ:IMRN) shares decreased by 16.9% to $1.61. The market value of their outstanding shares is at $9.1 million.
    • Ambrx Biopharma (NYSE:AMAM) shares decreased by 16.27% to $1.64. As of 12:30 EST, this security is trading at a volume of 471.9K shares, making up 14.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $63.3 million.
    • Gossamer Bio (NASDAQ:GOSS) shares declined by 14.88% to $1.66. As of 12:30 EST, this security is trading at a volume of 2.6 million shares, making up 61.0% of its average full-day volume over the last 100 days. The company's market cap stands at $156.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVO
    $AMAM
    $ATNF
    $BXRX

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    Oric Pharmaceuticals Inc.
    $ORIC
    1/7/2026$22.00Overweight
    Piper Sandler
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Alvotech
    $ALVO
    12/9/2025$5.00Underweight
    Barclays
    Oric Pharmaceuticals Inc.
    $ORIC
    11/20/2025$25.00Outperform
    Evercore ISI
    More analyst ratings

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Gossamer Bio from Outperform to Market Perform and set a new price target of $1.00

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ekblom Anders

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:16 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bender Jeremy

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:15 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pakianathan Deepika

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:13 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 10:44:05 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    SEC Filings

    View All

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    3/5/26 8:03:36 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Gossamer Bio Inc.

    SCHEDULE 13G - Gossamer Bio, Inc. (0001728117) (Subject)

    3/2/26 11:57:56 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    2/27/26 9:58:50 PM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 2, 2026 (the "Grant Date"), ORIC granted a total of 14,800 non-qualified stock options and 2,400 restricted stock units to one new non-executive employee who began their employment with ORIC in February 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stoc

    3/6/26 4:30:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

    MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time). A copy of the presentation slide deck is available on the Company's website: https://investors.immuron.com.au/announcements/7418301 COMPANY CONTACT: Steven LydeamoreChief Executive [email protected] About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing

    3/5/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

    REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). To listen to the webcast, register here: Q4 and Full Year 2025 webcast registrationTo participate in the Q&A, register here: Q4 and Full Year 2025 conference call registration Slid

    3/4/26 3:00:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director You Angie bought $262,899 worth of shares (28,000 units at $9.39) (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    6/23/25 8:05:17 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hasnain Faheem bought $250,282 worth of shares (372,000 units at $0.67) (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    6/24/24 5:52:18 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Leadership Updates

    Live Leadership Updates

    View All

    ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

    Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study Expect to report multiple cli

    1/12/26 8:30:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alvotech announces planned CEO succession and leadership transition

     - Róbert Wessman to continue serving as Executive Chairman in full-time capacity - Lisa Graver appointed Chief Executive Officer REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company's inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capac

    1/6/26 7:15:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

    Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC's transition to potential late-stage development Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) Expects to report four clinical data readouts across ORIC-944 and enozertinib (ORIC-114) programs through mid-2026, ahead of potential initiat

    11/13/25 4:10:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:54:12 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:47:31 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:14:58 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Financials

    Live finance-specific insights

    View All

    Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

    REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). To listen to the webcast, register here: Q4 and Full Year 2025 webcast registrationTo participate in the Q&A, register here: Q4 and Full Year 2025 conference call registration Slid

    3/4/26 3:00:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

    Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- OR

    12/5/25 8:00:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVO
    $AMAM
    $ATNF
    $BXRX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care